PTD-DBM: what it is, what the mouse studies found and what is unknown

PTD-DBM is a research peptide built from two parts. The DBM, or Dishevelled-binding motif, is a short stretch of the human protein CXXC5 that lets it bind to Dishevelled (Dvl), a central component of the Wnt/β-catenin signalling pathway. The PTD, or protein transduction domain, is a cell-penetrating sequence attached so that the motif can cross cell membranes and reach Dishevelled inside the cell. Together they make a peptide of about 3083 g/mol, much larger than the cosmetic tripeptides and pentapeptides sold alongside it, such as AHK-Cu and Pal-GHK.

The peptide came out of work on CXXC5 by Kang-Yell Choi’s laboratory at Yonsei University. In a 2015 paper in the Journal of Experimental Medicine, the group reported that CXXC5 acts as a negative feedback regulator of the Wnt/β-catenin pathway by binding Dishevelled, that CXXC5 levels fall in the keratinocytes and fibroblasts of acute human wounds, and that mice lacking CXXC5 heal skin wounds faster with more keratin and collagen. PTD-DBM was made as a tool to break the CXXC5–Dishevelled interaction: in cells it activated β-catenin and collagen production, and applied to skin wounds in mice together with valproic acid it accelerated healing synergistically ^[1].

Two years later the same group turned to hair. Their 2017 paper in the Journal of Investigative Dermatology found that CXXC5 was raised in the miniaturised hair follicles and arrector pili muscles of human balding scalps, that it suppressed alkaline phosphatase activity and proliferation in human dermal papilla cells, and that mice lacking CXXC5 regrew hair faster. Disrupting the CXXC5–Dishevelled interaction with the competitor peptide activated Wnt/β-catenin signalling and accelerated both hair regrowth and wound-induced hair follicle neogenesis in mice ^[2]. An accompanying commentary in the same journal described CXXC5 as a negative regulator worth targeting in hair follicle regeneration ^[3]. That paper is why PTD-DBM is sold as a hair peptide, and it is the strongest evidence for it. For how the research peptide market works, see what research peptides are.

Hair follicles cycle between growth (anagen), regression and rest, and the Wnt/β-catenin pathway is the main signal that pushes a resting follicle back into growth and that drives the formation of new follicles after wounding. When the pathway is on, β-catenin accumulates in the cell and switches on growth genes; when it is off, an enzyme complex containing GSK-3β tags β-catenin for destruction. Dishevelled is the protein that, on receiving a Wnt signal, restrains that destruction complex. CXXC5 binds Dishevelled and dampens the signal, a feedback loop that keeps Wnt activity in check ^{[1] [2]}.

PTD-DBM copies the part of CXXC5 that binds Dishevelled. Once inside the cell it competes with CXXC5 for that binding site, so CXXC5 can no longer restrain Dishevelled, and Wnt/β-catenin signalling runs at a higher level than it otherwise would. It does not add Wnt; it removes a brake. That is why it works best in combination with valproic acid, an anti-epileptic drug that inhibits GSK-3β and so blocks β-catenin destruction from a different direction. In the 2015 wound study, the two together accelerated healing more than either alone ^[1], and in the 2017 hair study valproic acid further increased regrowth in CXXC5-deficient mice, mimicking what the peptide does ^[2].

A 2023 paper from the same group added a mechanism relevant to pattern hair loss. Prostaglandin D2 (PGD2) is a known inducer of hair loss, and dihydrotestosterone (DHT), the androgen behind male pattern baldness, raises PGD2. The study found that CXXC5 mediates the hair loss caused by PGD2, that hair loss induced by PGD2 was restored by knocking out CXXC5 or by treating with PTD-DBM, that PTD-DBM also overcame the suppression of new follicle formation by PGD2 in the wound-induced hair neogenesis model, and that DHT-induced hair loss was alleviated by inhibiting both GSK-3β and CXXC5 ^[4]. That links the peptide to the DHT pathway that finasteride targets, though only in mice.

Two features of the mechanism matter for anyone reading about PTD-DBM. First, it is a general Wnt activator, and the Wnt/β-catenin pathway is involved in tissue growth throughout the body, including in several cancers; a peptide that removes a brake on it is not a molecule to assume is harmless if it goes somewhere other than a hair follicle. Second, the same group has since developed small molecules that inhibit both GSK-3β and the CXXC5–Dishevelled interaction in one compound ^[7], which suggests the peptide is a proof of concept rather than the form the researchers expect to bring to patients.

The PTD-DBM benefits claimed by sellers are hair regrowth in pattern baldness, growth of entirely new follicles, and faster, scar-free wound healing. Searches for PTD-DBM hair growth, PTD-DBM results and PTD-DBM vs minoxidil reflect those claims. Every one of them rests on mouse experiments.

Hair regrowth: in the 2017 study, the peptide accelerated hair regrowth in mice whose hair had been removed to synchronise the follicle cycle, and it increased wound-induced hair neogenesis, the formation of new follicles in the centre of large wounds ^[2]. The 2023 study showed it could counteract hair loss induced by PGD2 in mice ^[4]. Both are positive, well-controlled animal results from a laboratory with a strong track record on this pathway. Neither involved a human scalp. Mouse hair cycles are short and synchronised, the mouse model of neogenesis has no direct human equivalent, and pattern hair loss in people is a slow, androgen-driven miniaturisation that no mouse model fully reproduces.

Wound healing: the 2015 study showed accelerated closure of mouse skin wounds with PTD-DBM plus valproic acid ^[1]. A 2023 study delivered the peptide and valproic acid from an adhesive hyaluronic acid hydrogel patch and reported regenerative healing in mice, with less scar formation, reduced expression of the myofibroblast marker α-SMA, more stem cell markers and more collagen III, a marker of scarless, fetal-type healing ^[5]. Again the setting was mouse skin.

PTD-DBM vs minoxidil: there is no head-to-head study. Minoxidil and finasteride have decades of clinical trial data in people; PTD-DBM has none. A 2025 review of Wnt-pathway approaches to hair regrowth describes PTD-DBM as an emerging therapy with potential to outperform existing options but states that these therapies require further research to validate their efficacy and to understand their risk profile ^[6]. A 2025 review of hair-loss cosmeceuticals makes the same general point about peptides: effectiveness and safety substantiation remain the field’s main challenge ^[8].

What can be said in the peptide’s favour is that its pathway has some human support from a different compound. Topical valproic acid, the GSK-3β inhibitor the peptide is paired with, increased total hair counts over 24 weeks in a randomised, placebo-controlled trial of 40 men with androgenetic alopecia, with mostly mild adverse events ^[9]. That shows Wnt activation on the human scalp can grow hair. It does not show that PTD-DBM does.

There are no human trials of PTD-DBM and no registered clinical study as of September 2026. We searched ClinicalTrials.gov for the peptide under its name and for CXXC5-targeting interventions and found nothing. The only human material in the literature is the tissue work in the 2017 paper, which measured CXXC5 in balding human scalp samples and tested the peptide on cultured human dermal papilla cells ^[2]. Anecdotal reports on forums, and before-and-after photographs on retail sites, are not studies, and the peptide’s size and design make it an unusually poor candidate for do-it-yourself testing, as the sections on route and safety explain.

In mice, hair regrowth after depilation was assessed over a few weeks, and wound healing over days to weeks ^{[1] [2]}. Those timescales reflect the mouse hair cycle and cannot be transferred to people, whose scalp follicles spend years in growth phase and months in rest. Any genuine treatment for pattern hair loss needs three to six months before a change in hair count can be measured, which is the duration the valproic acid trial used ^[9]. There are no data on PTD-DBM at any human timescale.

PTD-DBM dosage in the literature means the amounts applied to mouse skin, alone or with valproic acid, in the Yonsei studies ^{[1] [2] [4] [5]}. The peptide was applied topically to shaved dorsal skin or to wounds, and in the 2023 patch study it was loaded into a hydrogel. The exact concentrations are given in the papers’ methods and are laboratory quantities for a 25 g animal; they are not doses for a person and are not recommendations. No study has established a topical concentration for human scalp, and there has never been a dose-ranging study of any kind.

No published study has injected PTD-DBM into any animal or person, so there is no injected dose to report. Research stores sell vials of 5 mg and 10 mg, quantities with no relationship to anything in the literature. The peptide calculator converts vial contents into a solution concentration; it cannot supply a dose that no study has tested.

Every published use of PTD-DBM is topical: solution applied to mouse skin or wounds, or a hydrogel patch ^{[1] [2] [4] [5]}. That is deliberate. The protein transduction domain gets the peptide into cells, but it has no tissue selectivity, so applying it where it is wanted, on skin, and nowhere else, is part of the design. A 3 kDa peptide is much larger than the small cosmetic peptides whose skin penetration has been measured, and microneedle delivery, which increased small-peptide delivery into human skin many-fold in one study ^[10], is one way such a molecule might be delivered in future. The hydrogel patch in the 2023 study is a step in that direction ^[5].

Research peptide suppliers sell PTD-DBM as a lyophilised powder in the same vials as injectable peptides. Some buyers dissolve it for scalp application, which at least matches the published route; the mouse studies do not tell anyone what concentration to use, and a home-made solution of a cell-penetrating peptide has none of the controls of a laboratory experiment. Injecting PTD-DBM, whether into the scalp or under the skin, has never been studied in any species. A cell-penetrating Wnt activator injected into tissue would enter whatever cells it met, and the consequences of that are unknown.

PTD-DBM side effects have never been assessed in people, and the mouse papers were efficacy studies rather than toxicology. Nothing in them reports harm from topical application over the periods studied ^{[1] [2] [4] [5]}, but that is a different thing from a safety study.

The concern that any reviewer would raise is the pathway. Wnt/β-catenin signalling drives cell proliferation in many tissues, and its inappropriate activation is a feature of several cancers, most famously colorectal cancer, as well as of fibrotic conditions. The 2015 paper itself noted that the pathway plays roles in dermal fibrosis as well as healing ^[1]. A peptide that removes a natural brake on Wnt signalling, fused to a domain that carries it into any cell, is a research tool whose whole-body effects nobody has measured. The 2025 review of Wnt-based hair therapies makes the same point in general terms: their risk profile needs further study ^[6]. The same laboratory’s move towards small-molecule dual inhibitors ^[7] may partly reflect the difficulty of controlling where a cell-penetrating peptide acts.

Two practical points follow. First, the valproic acid that PTD-DBM is usually paired with in the mouse work is a prescription anti-epileptic with its own well-known toxicity, including teratogenicity, and the topical trial that supported it in men reported a case of ventricular tachycardia that the authors judged unrelated ^[9]; combining a research peptide with a drug outside a clinical setting compounds the unknowns. Second, a 3 kDa peptide of unusual sequence is harder to synthesise cleanly than a tripeptide, so purity and identity testing matter more than for most products sold under a cosmetic heading.

PTD-DBM is not an approved medicine anywhere, is not a listed cosmetic ingredient, and has no marketing authorisation of any kind. It is an academic research compound. It has not been the subject of any FDA compounding decision and is not on the WADA Prohibited List. Any product claiming to treat hair loss with it is making a medicinal claim without a licence. Sold as a research chemical in a vial, it falls under the general rules for research peptides; see our legal status overview, with pages for the UK and the US.

Lyophilised PTD-DBM is stored cold, dry and away from light, like other peptides; see how to store peptides. Its formula contains two sulphur atoms, so it carries sulphur-bearing residues that are prone to oxidation once in solution, and reconstituted material should be refrigerated and used quickly. Bacteriostatic water is the usual laboratory solvent. Arginine-rich cell-penetrating sequences are highly water-soluble, so the peptide should dissolve readily, unlike the palmitoylated cosmetic peptides.

PTD-DBM is long, arginine-rich and expensive to synthesise well, so it is one of the pricier compounds in the hair category, and quality varies. Compare PTD-DBM prices across suppliers, and check listings in the UK and the US; peptide prices explained covers how stores set prices.

A certificate of analysis for PTD-DBM should show a measured mass close to 3083 g/mol and an HPLC purity figure from an independent laboratory; for a peptide this long, a purity in the low nineties or below means a substantial fraction of truncated or deleted sequences that may not carry a working transduction domain or binding motif. Our guides to reading a COA, third-party testing and spotting a fake supplier explain what to look for, and our list of third-party tested suppliers shows which stores publish independent results. For other compounds sold for hair, see peptides for hair growth and the GHK-Cu guide.